Elia™ dsDNA 法在 HEp-2 细胞间接免疫荧光阴性患者中检测抗 dsDNA 抗体的临床相关性
该研究回顾性分析 234 例 Elia™ dsDNA 法可检出抗 dsDNA 抗体的连续受试者病历。其中 124 例 IIF 阴性但 Elia™ CTD 筛查法 ANA 阳性或临界,仅 6/49 例 AASARD 患者与 118/185 例非 AASARD 受试者抗 dsDNA 浓度无统计学差异(p=0.53)。结论提示 IIF 阴性者检出抗 dsDNA 抗体部分有临床意义,支持 IIF 与固相法联合筛查 ANA。
要点
- IIF 阴性但 Elia™ dsDNA 法可检出抗 dsDNA 抗体的患者中,部分 AASARD 病例具有临床相关性。
- AASARD 与非 AASARD 组间抗 dsDNA 抗体浓度无统计学显著差异(p=0.53)。
- 建议 ANA 筛查联合使用 IIF 与固相法,以避免遗漏潜在重要的自身抗体。
核心结论
- IIF 阴性患者中检出抗 dsDNA 抗体在某些病例中具有临床相关性。
- 结果支持 ANA 筛查算法中联合使用 IIF 与固相法,以避免遗漏潜在重要自身抗体。
研究设计与样本
- 回顾性研究,连续纳入 234 例经 Elia™ dsDNA 法可检出抗 dsDNA 抗体的受试者并审查其病历。
主要发现
- 124 例 IIF 阴性受试者经 Elia™ CTD 筛查法 ANA 呈阳性或临界。
- 该组中 6/49 例(12%)为 AASARD,118/185 例(64%)为非 AASARD。
- AASARD 与非 AASARD 组间抗 dsDNA 抗体浓度无统计学显著差异(p=0.53)。
- AASARD 组中 4 例抗 dsDNA 抗体阳性,分别诊断为 SLE(已治疗)、盘状红斑狼疮(未治疗)、未分化结缔组织病(未治疗)和多发性肌炎(已治疗)。
- AASARD 组中 2 例抗 dsDNA 抗体为临界浓度,均为已治疗 SLE,其中 1 例处于缓解期。
关键数值与推荐
- 抗 dsDNA 抗体浓度在 AASARD 与非 AASARD 组间比较 p=0.53。
临床怎么用
- 对 IIF 阴性但固相法可检出抗 dsDNA 抗体的患者,应结合临床评估其潜在临床意义。
- ANA 筛查建议联合使用 IIF 与固相法,以减少遗漏重要自身抗体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Data on the clinical importance of the detection of anti-dsDNA antibodies in patients with negative indirect immunofluorescence on the HEp-2 cell (IIF) are sparse and are especially not available for all common commercially available assays. This study aimed to assess the clinical significance of anti-dsDNA antibodies determined by the Elia™ dsDNA assay in patients with negative IIF. METHODS: We retrospectively examined the medical records of 234 consecutive subjects with detectable anti-dsDNA antibodies determined by the Elia™ dsDNA assay. RESULTS: A total of 124 subjects with detectable anti-dsDNA autoantibodies were IIF-negative, but yielded positive or borderline results in the Elia™ CTD screen assay for antinuclear antibodies (ANA). Within this group, 6/49 IIF-negative patients (12%) with ANA-associated systemic autoimmune rheumatic disorders (AASARD) and 118/185 subjects (64%) with various other diseases (Non-AASARD) were identified. There was no statistically significant difference with regard to the concentrations of anti-dsDNA antibodies (p=0.53) between the AASARD and the Non-AASARD group. Within the AASARD group, four patients diagnosed with systemic lupus erythematosus (SLE, treated), discoid lupus erythematosus (untreated), indetermined connective tissue disease (untreated) and polymyositis (treated) had positive anti-dsDNA autoantibodies, whereas two patients with treated SLE, thereby one in remission, had borderline concentrations of anti-dsDNA antibodies. CONCLUSIONS: Our findings suggest that the detection of anti-dsDNA antibodies in IIF-negative patients can be of clinical relevance in some cases. Our results further support the combined use of IIF and solid-phase assays in screening algorithms for ANA, in order to avoid overlooking potentially important autoantibody entities.
引用
- Robier C, Haas M, Quehenberger F, et al. The clinical relevance of anti-dsDNA antibodies determined by the Elia™ dsDNA assay in patients with negative indirect immunofluorescence on the HEp-2 cell. Clin Chem Lab Med. 2020. PMID: 33064668. doi:10.1515/cclm-2020-1408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。